Abstract
The development of genomics-based molecular diagnostics that are linked to
therapeutic products is critical to targeted drug developments of the future.
The potential for molecular diagnostics to be used as companion products for
personalized treatments that are based on patient characteristics will
contribute to a growing trend for new partnerships between drug companies and
diagnostic firms. ' Key Trends in Drug-Diagnostic Co-Development' is a new
report published by Business Insights that explores the potential for applying
genomic-based diagnostics to new drug developments, and the resultant
implications for the pharma/biotech and diagnostic industries. This report
examines the commercial and regulatory challenges facing drug-diagnostic
combinations and evaluates emerging business models to identify the most
effective forms of pharmacodiagnostic partnership. This report also reviews 28
collaborative agreements for the co-development of drug-diagnostics and
determines which combinations can be expected to result in commercial products
in the near future.
| 
View Cart
